We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 988

Advice of counsel defense in US v. Lauren Stevens: dismissal of indictment is not necessarily good news for companies
  • Hogan Lovells
  • USA
  • March 25 2011

The indictment last November of former GlaxoSmithKline (GSK) in-house counsel, Lauren Stevens, for purportedly obstructing a U.S. Food and Drug Administration (FDA) investigation into whether GSK marketed Wellbutrin, an anti-depressant drug, off-label, falsifying and concealing documents, and making false statements sent shockwaves through the legal community

D.C. Circuit decision in Friedman v. Sebelius overturns exclusions of three Purdue pharma executives
  • Sidley Austin LLP
  • USA
  • August 6 2012

In the pharmaceutical industry, government investigations initiated by whistleblower qui tam complaints canand often doresult in both civil and criminal charges against the company

Former GSK in-house counsel Lauren Stevens acquitted
  • Kelley Drye & Warren LLP
  • USA
  • May 10 2011

Earlier today, Honorable Roger W. Titus, who is the judge presiding over the Lauren Stevens trial, granted the defendant's motion for a judgment of acquittal, bringing the case to an end

OIG Advisory Opinion 12-05 approves consumer rewards program
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • May 2 2012

In OIG Advisory Opinion 12-05, the OIG found that a consumer rewards program (the “Program”) offered by a supermarket chain with in-store and independent pharmacies (the “Requestor”) would not be subject to enforcement under the Anti-Kickback Statute (the “Kickback Statute”) or the beneficiary inducement prohibition found in the civil monetary penalties law (the “CMP Law”

Eli Lilly & Co
  • Dorsey & Whitney LLP
  • USA
  • June 24 2011

In an effort to solicit members for a class action, two law firms that represent shareholders in class actions against publicly traded companies are investigating certain officers and directors of Eli Lilly

Government puts in-house counsel in its cross-hairs
  • Venable LLP
  • USA
  • November 12 2010

Confirming recent statements by Department of Justice ("DOJ") and Food & Drug Administration ("FDA") officials that the government will increasingly target individual executives for criminal prosecution, DOJ has indicted a former Associate General Counsel for pharmaceutical giant GlaxoSmithKline ("GSK") on two counts of obstruction of justice and four counts of making false statements during an FDA investigation

Ten steps global life sciences companies should take in 2011
  • Sidley Austin LLP
  • USA
  • February 16 2011

Focus on potential kickback, Foreign Corrupt Practices Act, and Good Clinical Practice liability, especially in developing countries

“The elephant in the room”: indictment of former GlaxoSmithKline in-house attorney dismissed due to prosecutors’ misstatement of advice of counsel defense to grand jurors
  • Jenner & Block
  • USA
  • March 24 2011

A federal district court has dismissed the indictment of a former in-house counsel at pharmaceutical company GlaxoSmithKline ("GSK"), Lauren Stevens, who was charged in November 2010 with obstruction of a proceeding, false statements, and falsifying or concealing documents, for her role in responding to a document request from the Food and Drug Administration ("FDA"

U.S. v. Stevens: former GSK attorney acquitted on all counts
  • Ropes & Gray LLP
  • USA
  • May 16 2011

On May 10, 2011, Judge Roger Titus of the District of Maryland dismissed the case United States v. Stevens

Responding to a government subpoena or other document demand - six helpful hints
  • Ober Kaler
  • USA
  • December 31 2013

Presented by Gina L. Simms and James P. Holloway of OberKaler's Government Investigations and White Collar Defense Group, this podcast provides